InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,480.87
(
1.34%
)
US TECH 100
18,202.80
(
1.42%
)
Dow Jones
40,941.88
(
1.48%
)
Brent Oil
71.58
(
0.06%
)
Bitcoin
56,511.54
(
3.02%
)
Post# of 253065
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 838
Posts 120392
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 97508

Wednesday, 08/25/2010 8:43:25 AM

Wednesday, August 25, 2010 8:43:25 AM

Post# of 253065
BMY/PFE will present the full Apixaban dataset from the AVERROES study at ESC 8/31/10, as previously promised:

http://finance.yahoo.com/news/BristolMyers-Squibb-and-bw-3220893905.html?x=0&.v=1

Positive top-line data from this study were reported in June (#msg-51176226), which greatly improved the overall commercial prospects for Apixaban. However, the AVERROES study sidestepped the most important segment of the AF market insofar as it compared Apixaban to aspirin in patients unable to tolerate warfarin.

genisi and I predicted that BMY/PFE will defer submitting an NDA for Apixaban in AF until they have the results of the phase-3 study called ARISTOTLE, where Apixaban is compared to warfarin rather than aspirin (#msg-51490977).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up